Genomic testing in England runs on a published number: the turnaround time. Almost everything else about the service, from contract structure to laboratory staffing, is arranged around meeting it. What the service does not routinely publish is what it achieves, which is why the most useful documents about genomic turnaround are the ones that admit the target is missed.
Seven hubs, seven contracts
The national genomic testing service is delivered through seven Genomic Laboratory Hubs, each coordinating services for part of the country, supported by seven Genomic Medicine Service alliances in similar geographies. The hubs are led by Birmingham Women's and Children, Cambridge University Hospitals, Manchester University, Great Ormond Street, North Bristol, Newcastle upon Tyne Hospitals, and Guy's and St Thomas'.
From April 2026 that structure is held together by new contracts. NHS England awarded them through a Most Suitable Provider process rather than open competition, to seven existing providers, on the basis that they expand services already delivered. The approximate lifetime value across all lots is £5,175,000,000. Services start on 1 April 2026 and the initial period runs to 31 March 2034, with an option to extend by two further years.
The contract is the mechanism, and a written submission to the Health and Social Care Committee describes what it is meant to deliver. For the first time, service specifications will include turnaround time requirements, and new performance dashboards will make regional variation in access and speed visible to commissioners. The submission's assessment is measured: the test is whether commissioners use them.
The 42 days, and what is behind them
The commissioned turnaround time for inherited cancer testing is 42 days. East Genomic Laboratory Hub published an update on delays to inherited cancer testing stating the position plainly: while the commissioned turnaround time is 42 days, the current turnaround for tests flagged by ordering clinicians as priority is approximately three to four months. The 42 days is a specification. The three to four months is a measurement, and only one describes what a patient experiences.
The pattern repeats across test types. Oxford University Hospitals publishes the specified times it works to, running from three days for urgent prenatal and neonatal testing to 84 days for validation of diagnostic discovery cases. Whole genome sequencing carries a 42-day expectation for delivery of variants from sample receipt, and a further 42 days for validation and reporting at the hub. A single test can sit inside two consecutive 42-day windows before a result reaches a clinician.
The clearest account of why targets are missed concerns lung cancer, and identifies a structural problem. The national ambition, agreed at a Genomics England meeting in June 2023, is that the time from sample acquisition to full pathology and genomic results should be no more than 14 days. That is a pathway target covering the whole journey from biopsy to reported result. Genomic laboratories set their own 14-day targets for running the test alone, and the difference is the entire pathway: pathology, sample transfer and reporting sit outside the laboratory's clock. A submission to the Health and Social Care Committee states the consequence, that because the laboratory target covers only part of the pathway, results are often not reported within the 14-day target. The proposed correction is to set laboratory turnaround for lung cancer samples at seven days.
The United Kingdom Lung Cancer Coalition's report estimates up to 30,000 lung cancer patients a year require genomic testing, notes that delays in some regions extend into weeks despite the recommended 14-calendar-day maximum, and states that turnaround times are not routinely published. It recommends publishing turnaround data and letting services send samples to higher-performing laboratories.
What interpretation adds to the pipeline
Turnaround is half of what a genomic service does. The other half is deciding what a variant means, and that step has no turnaround target at all. A study published in Genetics in Medicine in 2023 by Rehm and colleagues examined more than 1.5 million sequencing test results from 19 clinical laboratories between 2020 and 2021. It found that 32.6 per cent of multi-gene panel tests were inconclusive because of variants of uncertain significance, against 22.5 per cent for exome and genome sequencing, a difference significant at P < .0001.
Those figures describe a category of result that is neither positive nor negative and cannot be resolved by working faster. A variant of uncertain significance arrives on time and still leaves the clinician without an answer, and as testing volume rises the number of such results rises with it. Sequencing capacity and interpretation capacity are different constraints, and the service measures one.
What the service does not publish
Three things are genuinely unknown, and the first is the most consequential. The service does not publish routine average turnaround times by test type and region. Individual hubs publish specified times and occasional delay notices; the national position is not available as a standing dataset, which is why a parliamentary submission can state that turnaround times are not routinely published and a charity report can call for them to be. The new dashboards are intended to close that gap, and are described in a contract rather than demonstrated in a publication.
Second, it is not known how the seven new contracts will change measured performance, as opposed to specified performance. They begin on 1 April 2026 and include turnaround requirements for the first time, and no post-contract performance data is published.
Third, the relationship between sequencing and interpretation capacity is not quantified anywhere in the public record. The variants of uncertain significance rate shows interpretation is a real constraint; it does not show how many results are waiting on it. Until those numbers are published, the honest summary is that the pipeline is specified in detail, measured in patches, and reported by laboratories that sometimes say plainly that they are behind.
Summary
England's genomic testing service is organised around turnaround targets that are specified in contracts and not routinely published as measurements, and the difference between those two things is what patients experience.
- Seven hubs, seven contracts, one structure. The Genomic Medicine Service runs through seven Genomic Laboratory Hubs, re-awarded from 1 April 2026 to 2034 at an approximate lifetime value of £5.175 billion.
- Turnaround requirements are new. The contracts include turnaround time requirements and performance dashboards for the first time; neither has yet produced published performance data.
- Targets and measurements diverge. The commissioned turnaround for inherited cancer testing is 42 days; East Genomic Laboratory Hub reports approximately three to four months for priority tests.
- The pathway target is not the laboratory target. The 14-day lung cancer ambition covers biopsy to reported result, while laboratories set 14 days for the test alone.
- Interpretation has no turnaround target. 32.6 per cent of multi-gene panel tests were inconclusive from variants of uncertain significance, against 22.5 per cent for exome and genome sequencing.
What is not published is average turnaround by test type and region, how the new contracts change measured performance, and how many results are waiting on interpretation rather than sequencing. The service knows its specifications. The figures that would show whether they are met are the ones still missing.
Research direction and editorial oversight: Juno Uni Hera. AI-assisted research and drafting; human review is ongoing.
Sources
- NHS England. Genomic Laboratory Hubs. NHS England (2026). https://www.england.nhs.uk/genomics/genomic-laboratory-hubs
- NHS England. The structure of the NHS Genomic Medicine Service. NHS England (2026). https://www.england.nhs.uk/genomics/the-structure-of-the-nhs-genomic-medicine-service
- NHS England. NHS Genomic Medicine Service. NHS England (2026). https://www.england.nhs.uk/genomics/nhs-genomic-medicine-service/
- Find a Tender Service. NHS Genomic Medicine Service - Most Suitable Provider Process (Notice 067976-2025). Find a Tender (2025). https://www.find-tender.service.gov.uk/Notice/067976-2025
- Health and Social Care Committee. Written evidence PMA0023 (Boehringer Ingelheim). UK Parliament (2026). https://committees.parliament.uk/writtenevidence/165565/html
- East Genomic Laboratory Hub. Inherited cancer test delays update. East Genomics (2026). https://www.eastgenomics.nhs.uk/for-healthcare-professionals/updates/inherited-cancer-test-delays-update
- Oxford University Hospitals. Turnaround times for Genetic/Genomic testing. OUH (2026). https://www.ouh.nhs.uk/media/t0ck3r2h/turnaround-times.pdf
- United Kingdom Lung Cancer Coalition. Faster Testing, Better Outcomes: Genomic Testing in Lung Cancer. UKLCC (2025). https://www.uklcc.org.uk/sites/default/files/2025-03/FINAL_WEB%20VERSION__Faster%20Testing%20Better%20Outcomes%20Genomic%20Testing%20in%20Lung%20Cancer.pdf
- Rehm HL, et al. The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change. Genetics in Medicine 25(12):100947 (2023). https://pubmed.ncbi.nlm.nih.gov/37534744/
- Genomics Education Programme. Genomic Laboratory Hubs. NHS England (2026). https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/genomic-laboratory-hubs